2001 and Targeted Protein Degradation

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2001

Targeted Protein Degradation

Targeted protein degradation: turning undruggable targets into druggable targets

Drug Target Review

JULY 6, 2023

Unlike traditional drug discovery, which focuses on inhibiting or activating proteins, TPD offers a more precise and efficient way to alter cellular pathways. 1 The concept of TPD was first demonstrated with a heterobifunctional small molecule to degrader a protein of interest in the early 2000s. How does TPD work? Nature News.

Targeted Protein Degradation

Targeted Protein Degradation Small Molecule Clinical Trials Science

Biotech Risk Cycles: Assets And Platforms

LifeSciVC

OCTOBER 28, 2024

Here’s a history lesson on these asset-platform cycles… In 1999-2001, biotech experienced what is widely called the “genomics bubble” – venture capitalists and public market investors fueled an ebullient moment in the markets (alongside an even larger dot.com bubble). Intellia, Kymera , Dyne, Replimune, etc).

Licensing

Licensing Licensing Marketing Targeted Protein Degradation

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Drug Discovery Digest

Targeted protein degradation: turning undruggable targets into druggable targets

Biotech Risk Cycles: Assets And Platforms

Webinars

Stay Connected